Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACA 125 (Abagovomab) in Recurrent Ovarian Cancer
NCT00103545Phase 2Completed
- Sponsor
- AGO Study Group
- Start
- Jul 2003
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of abagovomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AGO Study Group. Started Jul 2003; status: completed.
02
Drugs
abagovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00103545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103545.